Global Breast Cancer Market – Overview
Breast cancer patients develop cancer in the cells of their mammary glands which has a very high change of spreading to its adjacent tissues or lymph nodes. Presence of breast plump, red patches on the breast skin and painful sore breast are some symptoms associated with breast cancer. According to WHO it is the second most common cancer in women.
Get Premium Sample copy @ https://www.marketresearchfuture.com/sample_request/1379 .
Global breast cancer market has seen a huge rise owing to early menarche, genetic predisposition rising female geriatric population base, and menopause. Moreover positive trends in medical imaging, accuracy of diagnostic methods, use of novel drug therapies such as albumin-bound nanoparticle drugs & cancer biomarkers, awareness against breast cancer and favourable reimbursement policies are aiding to augmentation of breast cancer market growth curve. High cost of treatments, unaffordability in middle income countries and side effects associated with the treatments may hinder the market growth during the forecast period.
Key players for Global Breast Cancer Market:
Pfizer (US), Novartis AG (Switzerland), Oncogenex (US), Apthera Inc (UK), BioNumerik Pharmaceuticals (US), Oncothyreon Inc (US), Astellas (Japan), Bipar Sciences (US), Puma Biotechnology (US), Sanofi S.A. (US), Eli Lilly and Company (US), AstraZeneca (UK), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline (UK), Genentech (US), Teva Pharmaceutical Industries (Israel), Sun Pharmaceutical Industries Ltd (India), Accord Healthcare, Inc. (India), Gilead Sciences, Inc. (US), Bristol-Myers Squibb company (US), Actavis, Inc. (US), Hospira, Inc. (US), Bayer AG (Germany).
Global Breast Cancer Market- competitive Analysis
Pfizer is one of the world’s largest pharmaceutical companies which headquartered in US. The Company got FDA approval of IBRANCE for the first line HR+, HER2- metastatic breast cancer in March 2017. It is the only cyclin-dependent kinase 4/6 inhibitor that is approved by the FDA as a first line therapy. In 2016, Pfizer has acquired Medivation to further increase its oncology market.
AstraZeneca is a multinational pharmaceutical company with a huge global presence which is headquartered in UK. In 2017, company got approval for three new drugs. Lynparza is one of them which is a PARP inhibitors. This drug has shown very promising results in clinical Phase III trials and may be able to generate $1.2 billion by 2020.
Get Prime Discount @ https://www.marketresearchfuture.com/check-discount/1379 .
Global Breast Cancer Market – Regional Analysis
North America’s breast cancer market is known to be the largest, owing to high prevalence of hypertension, increasing obese population, increasing acceptance of new technologies, increasing geriatric population, growing clinical research and development sector, sophisticated healthcare infrastructure and presence of pharmaceutical giants. Additionally, the presence of a large customer base in this region is likely to propel the growth of the market in North America. For instance, according to the stats presented by breast cancer organisation about 12.4% of U.S. women will develop invasive breast cancer over the course of her lifetime.
Europe is second leader in the diabetic neuropathy market. The European market is predicted to grow during the forecast period due to various government legislative reforms providing regulatory guidelines to manufacturing companies, the growing research and developments sector, established medical device market leading to accessibility to modern imaging techniques like Molecular breast imaging (MBI), poly-adenosine diphosphate ribose polymerase digital mammography, need for advanced treatments along with growing feminine health awareness. For instance, the European Commission stated that the R&D spending by the pharmaceuticals and biotechnology sectors grew by 8.7% in 2014. Furthermore according to UK cancer research organisation, In females in the UK, breast cancer is the most common cancer in females with around 54,800 new cases in 2015 in UK. Thus high patient pool and increasing clinical research and development sectors.
Asia Pacific is expected to be the fastest growing region in the global breast cancer market due to the presence of huge population suffering with diabetes, hypertension, growing healthcare investment and increasing geriatric population, rising abuse of alcohol. Delay in first child birth. For Instance in accordance to report published by the United Nations in 2015; between 2015 and 2030, the number of older persons aged 60 years or over in the world is predicted to grow by 56 %, from 901 million to more than 1.4 billion, out of which 66% of older population would reside in Asia-Pacific regions. This makes the females in this region prone to breast cancer, as the incidence of this disease increases after menopause. These countries are quickly adapting to new technologies so as to improve the health standard of countries. .Government is also supporting the same by investing in research and development in clinical research sector as well as in building proper healthcare infrastructure. Additionally due to positive market trends many key players are setting up their regional headquarters in this region and rising generic players in this region to attend to unmet needs of expensive treatments is further going to propel the market growth.
Get Customized Report @ https://www.marketresearchfuture.com/enquiry/1379 .
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar